Stifel raised the firm's price target on 10x Genomics to $20 from $15 and keeps a Buy rating on the shares. Q4 revenues were in-line with the pre-announcement and the FY26 guidance captures consensus, which "made for an uncontroversial conference call," the analyst tells investors in a post-earnings note. If Flex V2 adoption is robust and new project work allow single cell consumables to grow mid-single digits, "the stock can stay in favor," the analyst added.
